Intent to Issue a Single Source Purchase Order to arivis, AG for Acquisition of a Perpetual License and Maintenance and Support License for arivis Vision4D Software

THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF ACQUISITION AND GRANTS INTENDS TO NEGOTIATE AND AWARD A SINGLE SOURCE SIMPLIFIED ACQUISITION PURCHASE ORDER UNDER THE AUTHORITY OF FAR 13.106-1(b)(1)(i) TO ARIVIS AG (ARIVIS), EINSTEINSTRA'E 10, UNTERSCHLEI'HEIM, GERMANY, TO PURCHASE A PERPETUAL SOFTWARE LICENSE FOR VISION4D AS WELL AS SOFTWARE MAINTENANCE AND SUPPORT LICENSE FOR A BASE YEAR PLUS UP TO FOUR OPTION YEARS. THE MAINTENANCE AND SUPPORT WILL PROVIDE FDA CUSTOMERS WITH SOFTWARE UPDATES, BUG FIXES AND TECHNICAL SUPPORT FROM 09/30/2017 THROUGH 09/29/2018 AND UP TO FOUR ADDITIONAL YEARS OF MAINTENANCE AND SUPPORT (ULTIMATE COMPLETION IF ALL OPTIONS ARE EXERCISED 09/29/2022). THE FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) - MICROSCOPY AND IMAGING CORE FACILITY HAS IDENTIFIED ARIVIS VISION 4D AS THE ONLY STANDALONE IMAGE ANALYSIS SOFTWARE COMPATIBLE FOR ANALYSIS OF HUGE (HUNDREDS GIGABYTES TO TERABYTES) 4D DATA SETS THAT THE FDA PRODUCES WITH THE AGENCIES' LIVE OR FIXED FLUORESCENCE IMAGING SYSTEMS. VISION4D HAS BEEN DESIGNED TO WORK WITH EXTREMELY LARGE DATA SETS OF UP TO 6 TERABYTES AND HAS MULTIPLE HIGH QUALITY VOLUME AND SURFACE RENDERING OPTIONS. NO OTHER SOFTWARE IDENTIFIED BY THE FDA SUCH (AXIOVISION, METAMOLPH, IMARIS, VOLOCITY) CAN HANDLE EXTREMELY LARGE (ABOVE 500 GIGABYTES TO TERABYTES) 4D DATASETS. ADDITIONALLY, REMOTE ACCESS (FLOATING LICENSE) TO THE SOFTWARE BY USERS AND USE ON MULTIPLE COMPUTER PLATFORMS ARE ESSENTIAL TO THE FUNCTION OF THE CENTER'S CORE IMAGING FACILITY. OTHER IMAGE ANALYSIS SOFTWARE PACKAGES (E.G. AXIOVISION, METAMOLPH, VOLOCITY) DO NOT ALLOW FOR UNLIMITED REMOTE USE (MUST BE USED ONLY ON THE ONE PC IN WHICH THE SECURITY KEY IS INSERTED) AND NEED TO BE REPURCHASED FOR USE ON DIFFERENT COMPUTER PLATFORMS. BASED ON THE INHERENT SALIENT CHARACHERTISTICS OF THE BRAND NAME SOFTWARE, ARIVIS VISION4D IS THE ONLY SOFTWARE SOLUTION THAT MEETS THE FDA'S NEEDS. THE PROPOSED SIMPLIFIED ACQUISITION ACTION IS FOR PRODUCTS FOR WHICH THE GOVERNMENT INTENDS TO SOLICIT AND NEGOTIATE WITH ONLY ONE SOURCE. INTERESTED PERSONS MAY IDENTIFY THEIR INTEREST AND CAPABILITY TO RESPOND TO THE REQUIREMENT OR SUBMIT QUOTES WITHIN 10 CALENDAR DAYS AFTER THE DATE OF PUBLICATION OF THIS NOTICE. A DETERMINATION BY THE GOVERNMENT NOT TO COMPETE THIS PROPOSED SIMPLIFIED ACQUISITION BASED UPON RESPONSES TO THIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. INFORMATION RECEIVED WILL NORMALLY BE CONSIDERED SOLELY FOR THE PURPOSE OF DETERMINING WHETHER TO CONDUCT A COMPETITIVE REQUIREMENT. NO SOLICITATION IS AVAILABLE. ALL RESPONSIBLE VENDORS ARE ENCOURAGED TO SUBMIT A RESPONSE TO THIS NOTICE. FDA WILL CONSIDER ALL RESPONSES RECEIVED PRIOR TO THE CLOSING DATE OF THIS NOTICE AND WILL USE RESPONSES IN DETERMINING WHETHER IT IS NECESSARY TO USE FULL AND OPEN COMPETITION FOR THIS REQUIREMENT. FOR FURTHER INFORMATION, PLEASE CONTACT CONTRACT SPECIALIST ERIC FLAGG BY EMAIL AT ERIC.FLAGG1@FDA.HHS.GOV.